Empagliflozin in heart failure patients with preserved ejection fraction and diabetes mellitus type 2. (Results of a pilot prospective randomized trial)

Ovchinnikov A.G.; Borisov A.A.; Zherebchikova K.Yu.; Ryabtseva O.Yu.; Gvozdeva A.D.; Masenko V.P.; Ageev F.T.

doi:https://doi.org/10.17116/Cardiobulletin20211603160

Ovchinnikov A.G.

National Medical Research Center of Cardiology;
Moscow State University of Medicine and Dentistry

Borisov A.A.

National Medical Research Center of Cardiology

Zherebchikova K.Yu.

National Medical Research Center of Cardiology;
Sechenov First Moscow State Medical University

Ryabtseva O.Yu.

National Medical Research Center of Cardiology

Gvozdeva A.D.

National Medical Research Center of Cardiology

Masenko V.P.

National Medical Research Center of Cardiology

Ageev F.T.

Chazov National Medical Research Center of Cardiology

ORCID: 0000-0003-4369-1393

Empagliflozin in heart failure patients with preserved ejection fraction and diabetes mellitus type 2. (Results of a pilot prospective randomized trial)

Authors:

Ovchinnikov A.G., Borisov A.A., Zherebchikova K.Yu., Ryabtseva O.Yu., Gvozdeva A.D., Masenko V.P., Ageev F.T.

More about the authors

Journal: Russian Cardiology Bulletin. 2021;16(3): 60‑73

DOI: 10.17116/Cardiobulletin20211603160

Read: 2751 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Ovchinnikov AG, Borisov AA, Zherebchikova KYu, Ryabtseva OYu, Gvozdeva AD, Masenko VP, Ageev FT. Empagliflozin in heart failure patients with preserved ejection fraction and diabetes mellitus type 2. (Results of a pilot prospective randomized trial). Russian Cardiology Bulletin. 2021;16(3):60‑73. (In Russ.)
https://doi.org/10.17116/Cardiobulletin20211603160

Подписка 2026 Кардиологический вестник (Russian Cardiology Bulletin)

Использование инфографики авторами научных работ

Close metadata

OBJECTIVE

To evaluate the effect of sodium-glucose co-transporter-2 inhibitor empagliflozin on exercise tolerance and left ventricular (LV) diastolic function in patients with heart failure with preserved ejection fraction (HFpEF) and diabetes mellitus type 2 (T2DM).

MATERIAL AND METHODS

The prospective single-center open-label study included 80 patients with HFpEF and T2DM. All patients were assigned to empagliflozin group (10 mg daily; n=30) or the control group (n=30). Follow-up period was 24 weeks. Echocardiography data (et rest and during exercise), 6-minute walk test distance (6MWD) and serum NT-proBNP were analyzed at baseline and in 6 months after randomization.

RESULTS

After 24 weeks, the empagliflazin group was characterized by significantly greater 6MWD, less left atrial volume and LV filling pressure (E/e′ ratio and tricuspid regurgitation velocity), higher LV diastolic reserve (e′ velocity increment during exercise) and chronotropic (heart rate increment during exercise) reserves compared to the control group. In addition, significant between-group differences in serum NT-proBNP were found.

CONCLUSION

Empagliflozin improved exercise tolerance in patients with HFpEF and T2DM that was associated with less LV filling pressure and restoration of diastolic and chronotropic cardiac reserves.

Keywords:

left ventricle

diastolic dysfunction

filling pressure

diastolic stress test

heart failure with preserved ejection fraction

diabetes mellitus

empagliflozin

Authors:

Ovchinnikov A.G.

National Medical Research Center of Cardiology;
Moscow State University of Medicine and Dentistry

Borisov A.A.

National Medical Research Center of Cardiology

Zherebchikova K.Yu.

National Medical Research Center of Cardiology;
Sechenov First Moscow State Medical University

Ryabtseva O.Yu.

National Medical Research Center of Cardiology

Gvozdeva A.D.

National Medical Research Center of Cardiology

Masenko V.P.

National Medical Research Center of Cardiology

Ageev F.T.

Chazov National Medical Research Center of Cardiology

ORCID: 0000-0003-4369-1393

Received:

26.08.2021

Accepted:

31.08.2021

Close metadata

References:

Steinberg BA, Zhao X, Heidenreich PA, Peterson ED, Bhatt DL, Cannon CP, Hernandez AF, Fonarow GC; Get with the Guidelines Scientific Advisory Committee and Investigators. Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation. 2012;126(1):65-75. https://doi.org/10.1161/CIRCULATIONAHA.111.080770
Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: Comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. Journal of the American College of Cardiology. 2013;62(4):263-271. https://doi.org/10.1016/j.jacc.2013.02.092
Dhingra A, Garg A, Kaur S, Chopra S, Batra JS, Pandey A, Chaanine AH, Agarwal SK. Epidemiology of heart failure with preserved ejection fraction. Current Heart Failure Reports. 2014;11(4):354-365. https://doi.org/10.1007/s11897-014-0223-7
Saunders J, Mathewkutty S, Drazner M, McGuire DK. Cardiomyopathy in type 2 diabetes: Update on pathophysiological mechanisms. Herz. 2008;33(3):184-190. https://doi.org/10.1007/s00059-008-3115-3
van Melle JP, Bot M, de Jonge P, de Boer RA, van Veldhuisen DJ, Whooley MA. Diabetes, glycemic control, and new-onset heart failure in patients with stable coronary artery disease: data from the heart and soul study. Diabetes Care. 2010;33(9):2084-2089. https://doi.org/10.2337/dc10-0286
MacDonald MR, Petrie MC, Varyani F, Ostergren J, Michelson EL, Young JB, Solomon SD, Granger CB, Swedberg K, Yusuf S, Pfeffer MA, McMurray JJ; CHARM Investigators. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Heart Journal. 2008;29(11):1377-1385. https://doi.org/10.1093/eurheartj/ehn153
Hammoudi N, Jeong D, Singh R, Farhat A, Komajda M, Mayoux E, Hajjar R, Lebeche D. Empagliflozin improves left ventricular diastolic dysfunction in a genetic model of type 2 diabetes. Cardiovascular Drugs and Therapy. 2017;31(3):233-246. https://doi.org/10.1007/s10557-017-6734-1
Kusaka H, Koibuchi N, Hasegawa Y, Ogawa H, Kim-Mitsuyama S. Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome. Cardiovascular Diabetology. 2016;15(1):157. https://doi.org/10.1186/s12933-016-0473-7
Habibi J, Aroor AR, Sowers JR, Jia G, Hayden MR, Garro M, Barron B, Mayoux E, Rector RS, Whaley-Connell A, DeMarco VG. Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes. Cardiovascular Diabetology. 2017;16(1):9. https://doi.org/10.1186/s12933-016-0489-z
Fitchett D, Zinman B, Wanner C, Lachin JM, Hantel S, Salsali A, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME® trial investigators. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME trial. European Heart Journal. 2016;37(19):1526-1534. https://doi.org/10.1093/eurheartj/ehv728
Nagueh SF, Smiseth OA, Appleton CP, Byrd BF 3rd, Dokainish H, Edvardsen T, Flachskampf FA, Gillebert TC, Klein AL, Lancellotti P, Marino P, Oh JK, Popescu BA, Waggoner AD. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Journal of the American Society of Echocardiography. 2016;29(4):277-314. https://doi.org/10.1016/j.echo.2016.01.011
Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D, Picard MH, Rietzschel ER, Rudski L, Spencer KT, Tsang W, Voigt JU. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Journal of the American Society of Echocardiography. 2015;28(1):1-39.e14. https://doi.org/10.1016/j.echo.2014.10.003
Morris DA, Takeuchi M, Krisper M, Köhncke C, Bekfani T, Carstensen T, Hassfeld S, Dorenkamp M, Otani K, Takigiku K, Izumi C, Yuda S, Sakata K, Ohte N, Tanabe K, Osmanoglou E, Kühnle Y, Düngen H-D, Nakatani S, Otsuji Y, Haverkamp W, Boldt L-H. Normal values and clinical relevance of left atrial myocardial function analysed by speckle-tracking echocardiography: multicentre study. European Heart Journal. Cardiovascular Imaging. 2015;16(4):364-372. https://doi.org/10.1093/ehjci/jeu219
Blume GG, Mcleod CJ, Barnes ME, Seward JB, Pellikka PA, Bastiansen PM, Tsang TS. Left atrial function: physiology, assessment, and clinical implications. European Journal of Echocardiography. 2011;12(6):421-430. https://doi.org/10.1093/ejechocard/jeq175
Badano LP, Kolias TJ, Muraru D, Abraham TP, Aurigemma G, Edvardsen T, D’Hooge J, Donal E, Fraser AG, Marwick T, Mertens L, Popescu BA, Sengupta PP, Lancellotti P, Thomas JD, Voigt JU; Industry representatives; Reviewers: This document was reviewed by members of the 2016—2018 EACVI Scientific Documents Committee. Standardization of left atrial, right ventricular, and right atrial deformation imaging using two-dimensional speckle tracking echocardiography: a consensus document of the EACVI/ASE/Industry Task Force to standardize deformation imaging. European Heart Journal. Cardiovascular Imaging. 2018;19(6):591-600. https://doi.org/10.1093/ehjci/jey042
Pathan F, D’Elia N, Nolan MT, Marwick TH, Negishi K. Normal Ranges of Left Atrial Strain by Speckle-Tracking Echocardiography: A Systematic Review and Meta-Analysis. Journal of the American Society of Echocardiography. 2017;30(1):59-70.e8. https://doi.org/10.1016/j.echo.2016.09.007
Reddy YNV, Obokata M, Egbe A, Yang JH, Pislaru S, Lin G, Carter R, Borlaug BA. Left atrial strain and compliance in the diagnostic evaluation of heart failure with preserved ejection fraction. European Journal of Heart Failure. 2019;21(7):891-900. https://doi.org/10.1002/ejhf.1464
Pieske B, Tschöpe C, de Boer RA, Fraser AG, Anker SD, Donal E, Edelmann F, Fu M, Guazzi M, Lam CSP, Lancellotti P, Melenovsky V, Morris DA, Nagel E, Pieske-Kraigher E, Ponikowski P, Solomon SD, Vasan RS, Rutten FH, Voors AA, Ruschitzka F, Paulus WJ, Seferovic P, Filippatos G. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Heart Journal. 2019;40(40):3297-3317. https://doi.org/10.1093/eurheartj/ehz641
O’Keeffe ST, Lye M, Donnellan C, Carmichael DN. Reproducibility and responsiveness of quality of life assessment and six minute walk test in elderly heart failure patients. Heart. 1998;80(4):377-382. https://doi.org/10.1136/hrt.80.4.377
Redfield MM, Chen HH, Borlaug BA, Semigran MJ, Lee KL, Lewis G, LeWinter MM, Rouleau JL, Bull DA, Mann DL, Deswal A, Stevenson LW, Givertz MM, Ofili EO, O’Connor CM, Felker GM, Goldsmith SR, Bart BA, McNulty SE, Ibarra JC, Lin G, Oh JK, Patel MR, Kim RJ, Tracy RP, Velazquez EJ, Anstrom KJ, Hernandez AF, Mascette AM, Braunwald E; RELAX Trial. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA. 2013;309(12):1268-1277. https://doi.org/10.1001/jama.2013.2024
Abraham WT, Lindenfeld J, Ponikowski P, Agostoni P, Butler J, Desai AS, Filippatos G, Gniot J, Fu M, Gullestad L, Howlett JG, Nicholls SJ, Redon J, Schenkenberger I, Silva-Cardoso J, Störk S, Wranicz JK, Savarese G, Brueckmann M, Jamal W, Nordaby M, Peil B, Ritter I, Ustyugova A, Zeller C, Salsali A, Anker SD. Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes. European Heart Journal. 2021;42(6):700-710. https://doi.org/10.1093/eurheartj/ehaa943
Ovchinnikov AG, Potekhina AV, Ibragimova NM, Barabanova EA, Yushchyuk EN, Ageev FT. Mechanisms of exercise intolerance in patients with heart failure and preserved ejection fraction. Part I: The role of impairments in the left heart chambers. Kardiologiia. 2019;59(6S):4-16. (In Russ.). https://doi.org/10.18087/cardio.n394
Ovchinnikov AG, Potekhina AV, Borisov AA, Ibragimova NM, Yushchyuk EN, Valery P. Masenko VP, Ageev FT. The contribution of left atrial dysfunction to exercise intolerance in early heart failure with preserved left ventricular ejection fraction. European Heart Journal. Cardiovascular Imaging. 2019;21(suppl 1):1743. https://doi.org/10.1093/ehjci/jez320
Marrouche NF, Wilber D, Hindricks G, Jais P, Akoum N, Marchlinski F, Kholmovski E, Burgon N, Hu N, Mont L, Deneke T, Duytschaever M, Neumann T, Mansour M, Mahnkopf C, Herweg B, Daoud E, Wissner E, Bansmann P, Brachmann J. Association of atrial tissue fibrosis identified by delayed enhancement MRI and atrial fibrillation catheter ablation: the DECAAF study. JAMA. 2014;311(5):498-506. https://doi.org/10.1001/jama.2014.3
Pabel S, Wagner S, Bollenberg H, Bengel P, Kovács A, Schach C, Tirilomis P, Mustroph J, Renner A, Gummert J, Fischer T, Van Linthout S, Tschöpe C, Streckfuss-Bömeke K, Hasenfuss G, Maier LS, Hamdani N, Sossalla S. Empagliflozin directly improves diastolic function in human heart failure. European Journal of Heart Failure. 2018;20(12):1690-1700. https://doi.org/10.1002/ejhf.1328
Kolijn D, Pabel S, Tian Y, Lódi M, Herwig M, Carrizzo A, Zhazykbayeva S, Kovács A, Fülöp GA, Falcão-Pires I, Reusch PH, Linthout SV, Papp Z, van Heerebeek L, Vecchione C, Maier LS, Ciccarelli M, Tschöpe C, Mügge A, Bagi Z, Sossalla S, Hamdani N. Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase Gα oxidation. Cardiovascular Research. 2021;117(2):495-507. https://doi.org/10.1093/cvr/cvaa123
Madamanchi C, Alhosaini H, Sumida A, Runge MS. Obesity and natriuretic peptides, BNP and NT-proBNP: mechanisms and diagnostic implications for heart failure. International Journal of Cardiology. 2014;176(3):611-617. https://doi.org/10.1016/j.ijcard.2014.08.007
Januzzi JL Jr, Butler J, Jarolim P, Sattar N, Vijapurkar U, Desai M, Davies MJ. Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Type 2 Diabetes. Journal of the American College of Cardiology. 2017;70(6):704-712. https://doi.org/10.1016/j.jacc.2017.06.016
Pandey A, Khera R, Park B, Haykowsky M, Borlaug BA, Lewis GD, Kitzman DW, Butler J, Berry JD. Relative impairments in hemodynamic exercise reserve parameters in heart failure with preserved ejection fraction: a study-level pooled analysis. JACC. Heart Failure. 2018;6(2):117-126. https://doi.org/10.1016/j.jchf.2017.10.014
Huang PH, Leu HB, Chen JW, Wu TC, Lu TM, Ding YA, Lin SJ. Comparison of endothelial vasodilator function, inflammatory markers, and N-terminal pro-brain natriuretic peptide in patients with or without chronotropic incompetence to exercise test. Heart. 2006;92(5):609-614. https://doi.org/10.1136/hrt.2005.064147
Lin B, Koibuchi N, Hasegawa Y, Sueta D, Toyama K, Uekawa K, Ma M, Nakagawa T, Kusaka H, Kim-Mitsuyama S. Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice. Cardiovascular Diabetology. 2014;13:148. https://doi.org/10.1186/s12933-014-0148-1
Li Y, Li WM, Gong YT, Li BX, Liu W, Han W, Dong D, Sheng L, Xue JY, Zhang L, Chu S, Yang BF. The effects of cilazapril and valsartan on the mRNA and protein expressions of atrial calpains and atrial structural remodeling in atrial fibrillation dogs. Basic Research in Cardiology. 2007;102(3):245-256. https://doi.org/10.1007/s00395-007-0641-8
Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, Brunner-La Rocca HP, Choi DJ, Chopra V, Chuquiure-Valenzuela E, Giannetti N, Gomez-Mesa JE, Janssens S, Januzzi JL, Gonzalez-Juanatey JR, Merkely B, Nicholls SJ, Perrone SV, Piña IL, Ponikowski P, Senni M, Sim D, Spinar J, Squire I, Taddei S, Tsutsui H, Verma S, Vinereanu D, Zhang J, Carson P, Lam CSP, Marx N, Zeller C, Sattar N, Jamal W, Schnaidt S, Schnee JM, Brueckmann M, Pocock SJ, Zannad F, Packer M; EMPEROR-Preserved Trial Investigators. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. The New England Journal of Medicine. 2021;10.1056/NEJMoa2107038. https://doi.org/10.1056/NEJMoa2107038
ACC 2021 Late-Breaking Clinical Trial: Benefits of sodium glucose co-transporter-1/2 inhibition with sotagliflozin across the full spectrum of ejection fraction, including heart failure with preserved ejection fraction. Presented by D Bhatt on May 17, 2021. Accessed September 01, 2021. https://www.dicardiology.com/article/acc-2021-late-breaking-cardiology-study-results